Lupin 2024

Upsher-Smith acquires two products from Dr. Reddy’s

Print Friendly, PDF & Email

MAPLE GROVE, Minn. – Upsher-Smith recently announced that it has completed the acquisition of Tosymra (sumatriptan) Nasal Spray, 10 mg, and Zembrace SymTouch (sumatriptan) Injection 3 mg from Dr. Reddy’s Laboratories. The products were previously commercialized through Dr. Reddy’s wholly owned subsidiary, Promius Pharma. Both medications are indicated for the acute treatment of migraine with or without aura in adults.

“More than thirty-six million Americans suffer from migraines, and Upsher-Smith is proud to be diversifying our portfolio with two products that can bring pain relief to a significant number of patients suffering from acute migraine,” said Rusty Field, president and chief executive officer, Upsher-Smith. “We will be working diligently to ensure the smooth delivery of Zembrace SymTouch to patients, and to prepare for the launch of Tosymra, which we expect to take place toward the end of 2019.”

The addition of Tosymra and Zembrace SymTouch rounds out Upsher-Smith’s migraine product portfolio. The Company currently offers Qudexy XR (topiramate) Extended-Release Capsules, a once-daily treatment for use in the prevention of migraine headache in adults and adolescents 12 years of age and older.

Ballard Spahr, LLP served as the Company’s legal counsel on this transaction.


Comments are closed.